Teleflex Inc Stock Price, News & Analysis

Teleflex (NYSE: TFX) has received FDA 510(k) clearance for its new AC3 Range™ Intra-Aortic Balloon Pump (IABP). This innovative medical device is specifically designed for patient transport across various modes, including ambulances and aircraft.

The AC3 Range™ IABP builds upon the patented technology of the AC3 Optimus™ IABP, featuring a simple interface and proprietary algorithms for precise cardiac support. Key transport-focused features include:

• Full-size helium tank
• Dual power options
• Metal-reinforced extendable handle
• Four 360-degree swivel wheels

The device will enter full market release in the United States with shipments beginning in the second quarter of 2025. Teleflex will showcase both the AC3 Optimus™ and AC3 Range™ IABPs at the upcoming ISHLT Annual Meeting in Boston.

Teleflex (NYSE: TFX) announced preliminary results from its Ringer™ PBC IDE study at the CTO Plus Conference, investigating a novel perfusion balloon catheter for managing coronary perforations. The study enrolled 30 participants across four US sites.

The Ringer™ PBC features a unique helical balloon design allowing continuous coronary blood flow during inflation. Key results showed:

• Primary efficacy endpoint achieved in 73.3% of participants (22/30)
• Successful device delivery in 86.7% of cases (26/30)
• Control of extravasation with perfusion in 84.6% of successful deliveries (22/26)

The device has received FDA's Breakthrough Device Designation for coronary perforation management. Twelve participants required covered stent treatment post-procedure, one needed emergency surgery, and three deaths occurred despite controlled extravasation. A premarket application has been submitted to FDA.

Teleflex (NYSE: TFX) presented new findings from the CLEAR study at the 40th Annual European Association of Urology Congress in Madrid. The study, comparing UroLift™ System (PUL) with Rezūm™ Water Vapor Therapy (WVTT) for benign prostatic hyperplasia (BPH) treatment, revealed superior outcomes for UroLift™.

Key findings include:

• Only 1 out of 42 UroLift™ patients failed to achieve catheter independence within 3-7 days post-procedure, compared to 10 out of 37 Rezūm patients
• UroLift™ patients reported less interference with daily activities due to pain and blood in urine
• Better sexual function outcomes were observed in UroLift™ patients, with improved erectile and orgasmic function at one month
• Higher patient satisfaction scores were recorded for UroLift™ at both 14 days and one-month post-procedure

Cagent Vascular has appointed Paul Wilson as Chief Commercial Officer (CCO) to lead the company's commercial strategy. Wilson, who previously held senior leadership positions at Teleflex (TFX) and Abbott, will oversee sales, marketing, clinical programming, and business development initiatives.

The company's proprietary serration balloon technology, including the FDA-cleared Serranator® and Serranator SL-PRO™ PTA Serration Balloon Catheters, uses stainless steel micro-serration technology for vessel dilation in endovascular interventions. The technology delivers 1,000x more point force compared to traditional balloon angioplasty, creating linear, interrupted scoring during slow-and-low balloon inflation to optimize vessel preparation and enhance arterial expansion in peripheral artery disease (PAD) and chronic limb-threatening ischemia (CLTI).

Teleflex (NYSE: TFX) has announced its latest quarterly dividend declaration. The company's Board of Directors has approved a cash dividend of $0.34 per share of common stock. The dividend will be distributed on March 17, 2025, to shareholders who are on record as of the close of business on March 7, 2025.

Teleflex (NYSE: TFX) reported Q4 2024 revenues of $795.4 million, up 2.8% year-over-year, with adjusted diluted EPS of $3.89 compared to $3.38 in the prior year. Full-year 2024 adjusted revenue reached $3,061.1 million, up 2.9% from the previous year.

The company recorded a significant non-cash goodwill impairment charge of $240 million in the Interventional Urology unit, primarily due to subdued UroLift revenue growth expectations. For 2025 guidance, Teleflex projects adjusted constant currency revenue growth of 1.0% to 2.0% and adjusted diluted EPS of $13.95 to $14.35.

Two major strategic announcements were made: the planned acquisition of BIOTRONIK's Vascular Intervention business and the intention to separate Teleflex into two publicly traded companies. Additionally, the company plans to initiate a $300 million accelerated share repurchase program.

Teleflex (NYSE:TFX) announced that Chief Financial Officer Thomas E. Powell will retire effective April 1, 2025, after more than 13 years with the company. John R. Deren, currently Corporate Vice President and Chief Accounting Officer, will succeed as Executive Vice President and CFO effective April 2, 2025.

Powell will continue as a consultant through March 31, 2026, to ensure a smooth transition. Under his tenure, Teleflex achieved an 800 basis points increase in adjusted operating margin from 2012-2024. Deren, who joined Teleflex in 2013, brings over 30 years of financial management experience, having previously worked at PricewaterhouseCoopers, Rohm and Haas, Exelon Generation, and Trinseo.

Teleflex (NYSE:TFX) announced plans to separate into two independent publicly traded companies by mid-2026. The separation will be executed through a tax-free distribution of newly issued shares to shareholders.

The first company, RemainCo ($2.1B revenue in 2024), will focus on Vascular Access, Interventional, and Surgical businesses, targeting high-growth hospital-focused emergent markets. It's projected to deliver 6%+ constant currency revenue growth and double-digit EPS growth in the first year post-separation.

The second company, NewCo ($1.4B revenue in 2024), will comprise Urology, Acute Care, and OEM businesses. It's expected to generate low-single digit constant currency revenue growth with a mid-50% adjusted gross margin profile.

The separation aims to create two focused entities with simplified operating models, streamlined manufacturing footprints, and enhanced resource allocation. RemainCo will transition from 19 to 7 manufacturing facilities, with the remaining 12 transferring to NewCo.

Teleflex (NYSE:TFX) has announced a definitive agreement to acquire BIOTRONIK's Vascular Intervention business for approximately €760 million. The acquisition, expected to close by Q3 2025, will expand Teleflex's presence in the estimated $10 billion interventional cardiology and peripheral vascular market.

The acquired portfolio includes drug-coated balloons, drug-eluting stents, and other vascular intervention devices. In 2023, approximately 75% of revenues came from coronary interventions and 25% from peripheral interventional procedures. The business demonstrated a 5.4% constant currency revenue CAGR from 2022 to 2024 and is expected to generate approximately €91 million in revenues in Q4 2025.

Key products include the Pantera Lux Drug-Coated Balloon Catheter, PK Papyrus Covered Coronary Stent, and Orsiro Mission Drug Eluting Stent. The deal is expected to be approximately $0.10 accretive to adjusted earnings per share in the first year post-close.